Searched for
COMPETITIVE GENERIC THERAPY
Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for BioconIndian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...- Hetero partners with Richter to develop, market Semaglutide injection globallyHyderabad's Hetero Labs partners with European giant Gedeon Richter. They will jointly develop and sell Semaglutide Injection, the generic ...
- India’s anti-obesity drug market sees slower growth after initial surge in generic semaglutide salesIndia's anti-obesity drug market sees a slowdown after initial generic semaglutide sales. Demand has eased from its peak, with growth moder...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
- RPG Life Sciences bets big on API business, eyes GLP-1 entry by August-SeptemberRPG Life Sciences is prioritizing its API business for future growth, planning a significant acquisition to scale operations. The company a...
- Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
- Sun Pharma: How a small Kolkata trader became a global buyout artistSun Pharma, led by Dilip Shanghvi, is poised for its largest overseas acquisition, a $12.5 billion deal for Organon & Co. This move continu...
- Sun Pharma looks to outshine rival bids with $13 billion Organon offerSun Pharmaceutical is making its biggest move yet with a $13 billion offer for Organon & Co. This ambitious bid aims to transform the India...
- Novo Nordisk price cuts set to shake up India’s GLP-1 market, challenge genericsNovo Nordisk is slashing prices for its diabetes and weight loss drugs Ozempic and Wegovy in India. This move aims to make these treatments...
- Novo Nordisk plans to cut price of Ozempic as generics hit marketNovo Nordisk is set to lower the price of its popular weight loss and diabetes drug, Ozempic. This move comes after several Indian drugmake...
- Ajanta Pharma, Sun Pharma poised to tap GLP-1 opportunity amid market shift: Siddhartha KhemkaIndia's metabolic therapy market is transforming post-semaglutide patent expiry, shifting to a competitive, volume-driven model. With signi...
- A blockbuster unleashed: What happens when a big fat business explodes?India is set to experience a dramatic shift as Ozempic and Wegovy's active ingredient, semaglutide, becomes widely available. Over 40 India...
- Glenmark Pharmaceuticals wins USFDA nod for fluticasone inhalerGlenmark Pharmaceuticals has secured a significant approval from the US FDA for its inhaler fluticasone propionate. This marks a key step i...
- Obesity drugs shed niche tag, set to gain more weight in India pharmaIndia's obesity drug market is experiencing rapid growth, driven by rising lifestyle diseases and the launch of blockbuster therapies. The ...
- Indoco Remedies gets USFDA nod to market Lofexidine tablets with 180 days exclusivityIndoco Remedies Ltd was granted approval from the USFDA to sell its generic Lofexidine tablets, used for opioid withdrawal. This approval i...
- Zydus Lifesciences gets USFDA nod for generic rheumatoid arthritis treatment drugZydus Lifesciences has gained the US Food and Drug Administration's (FDA) approval to produce and market its Indomethacin suppositories. Th...
- Dr Reddy's launches generic epilepsy drug in US market"We are pleased that this product has been designated as a Competitive Generic Therapy (CGT) by the FDA," Dr Reddy's Laboratories North Ame...
- Desi pharma companies see big business in competitive genericsThe opportunity for domestic companies could cumulatively fetch up to a billion dollars in sales.
- Pharma cos focus on specialist therapiesPharma cos's emphasis is shifting to more focused therapies for specific cancers, immunological conditions and complex diseases.
Load More
